|Last Price$24.75||Day Change (%)0.04%|
|Open Price$24.75||Day Change ($)0.01|
|Day Range24.75–24.75||52-Week Range17.58–25.66|
As of Sat 12/09/2016 | USD
The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Mylan NV Investors
Watson Pharmaceuticals WPI scored big Tuesday when the Food and Drug Administration approved the firm's generic fentanyl patch. We may modestly increase our fair value estimate for Watson and will maintain our fair value estimate for competitor Mylan Laboratories MYL . The pain patch is one of the ...
Mylan Laboratories MYL reported impressive second-quarter results Wednesday. However, most of the improvement was temporary and will not affect our fair value estimate. The quarter was only slightly better than we expected after excluding a one-time litigation payment and proceeds from a product ...
Fitch:US Healthcare Outlook Stable Despite Political Uncertainty
Amyotrophic Lateral Sclerosis Market - Analysis, Technologies & Forecasts to 2021 - Key Vendors are GNT Pharma, Amkor Pharma & Sanofi - Research and Markets
Plus, a top executive bolts from eBay, Brazilian telcos get cheap, and more.
These mutual funds have far more than their recent success going for them.
Product durability, diversification, and cost synergies support strong earnings growth for this undervalued wide-moat firm.
Declining fuel prices stoked great returns at several of these companies, but that's not a lasting advantage.
Rising interest rates have taken their toll, but as the Fed delays dialing back on stimulus, investors are poised to recapture some of their losses.